Xevant, a provider of real-time pharmacy benefits intelligence, has introduced significant enhancements to its VerX Platform, unveiling four interconnected systems—Cortex, Pulse, Axis, and Nudge—to operationalize RxTech, a new segment aimed at transforming pharmacy benefits by eliminating prescription waste and achieving the lowest net cost for medications.
Xevant’s VerX Platform, powered by artificial intelligence (AI), is designed to deliver fully automated cost optimization and member engagement, asserting that the RxTech model is actively producing results in real-world pharmacy operations. The company states that RxTech, as an new technology segment, seeks to eliminate over $250 billion in prescription waste within the pharmacy benefits sector.
Brandon Newman, CEO and Founder of Xevant, commented on the platform’s evolution, stating, “When we launched VerX, we envisioned a platform for the next era of pharmacy benefits. Today, that vision is no longer theoretical. These interconnected systems — Cortex, Pulse, Axis, and Nudge — seamlessly and autonomously operate together to deliver real savings to every stakeholder in pharmacy.”The VerX Platform integrates these intelligent, interconnected systems to pursue the lowest net cost per claim while enhancing transparency, performance, and member outcomes across the pharmacy ecosystem. Cortex functions as an AI intelligence center, analyzing plan, claim, and member data to pinpoint savings opportunities and recommend actions. Pulse automates plan operations and performance management, converting static data into real-time intelligence. Axis connects VerX to various internal and market solutions, dynamically routing claims through the most cost-efficient channels, including PBMs, manufacturers, or cost-plus models. Nudge utilizes AgenticAI to engage members directly, facilitating the realization of identified savings opportunities.
Collectively, these systems form a closed-loop flywheel of continuous intelligence. This design aims to ensure that every insight generated translates into measurable savings, and every action taken by members contributes to improved health outcomes.
The announcement follows recent industry shifts, such as the TrumpRx–Pfizer agreement, which has highlighted a growing trend toward direct purchasing and rebate-free economic models in prescription drug distribution. Xevant states it has operationalized this shift through its VerX Platform by providing solutions such as employer-funded GLP-1 carve-outs, Cortex-driven patient assistance that eliminates out-of-pocket costs, and real-time drug optimization that routes claims to the most cost-effective channels.
Nick Conway, President at Value Pharmacy Services, provided an external perspective, noting, “The industry is clearly at an inflection point. Legacy models to manage a PBM can’t keep pace with the demand for transparency and real-time optimization. VerX brings the level of intelligence and automation needed to operate in the emerging PBM landscape — it’s a glimpse of where pharmacy infrastructure is headed.”Xevant positions itself as a leader in real-time pharmacy benefits intelligence, aiming to assist employers, brokers, and payers in gaining insight into drug costs and achieving measurable savings. The VerX Platform is presented as foundational to the RxTech era, integrating cost containment, optimization, integration, and member engagement.
